Eli Lilly’s Trulicity (dulaglutide) has, this week, been approved by the US FDA as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Our forecast report (click here to view) predicts that Trulicity will be the most prescribed GLP-1 agonist by 2022, surpassing current market leader Victoza (liraglutide; Novo Nordisk).
Once-weekly dosing, a convenient administration device, and good glycemic control gives Trulicity an advantage over earlier-to-market competitors such as Victoza, Bydureon (exenatide LAR; AstraZeneca) and Tanzeum (albiglutide; GlaxoSmithKline).
The launch of Trulicity comes very soon after GSK’s Tanzeum which was launched earlier this year. Both share a number of characteristics such as a once-weekly dosing schedule and administration via a small-gauge injection pen. Phase III clinical trial data indicate that Trulicity may be more effective than Tanzeum owing to its apparent greater control of HbA1c levels and weight-reducing properties. As such, Datamonitor Healthcare expects Trulicity to outperform Tanzeum in terms of sales revenue.
Datamonitor Healthcare analyst, Rajan Sharma, has forecast Trulicity revenues to overtake Novo Nordisk’s blockbuster once daily Victoza by 2022 across the US, Japan and five major EU markets by. By 2022 we predict Trulicity to achieve sales of $2,585million.
Trulicity currently is under review by the EMA and other regulatory bodies.
To find out more about our diabetes type 2 coverage click here. If you are already a subscriber click here to view our diabetes type 2 reports.
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: